adMare Bio Innovations
adMare BioInnovations is a Canadian mission-driven life sciences platform that provides early-stage capital, scientific and commercial expertise, turnkey lab facilities, and talent development to build and scale Canadian biotech companies. To date, it has helped create 39 companies with $5.8 billion in combined value.
- Company typePrivate
- Founded2019
- HeadquartersVancouver, Canada
- Headcount101–250
- GTM typeB2B
- OfferingServices
What adMare Bio Innovations does
adMare BioInnovations is a Canadian life sciences company creation engine formed in 2019 from the merger of CDRD (Centre for Drug Research and Development) and Neomed Institute. The organization is structured as a mission-driven, non-profit platform that provides early-stage capital, scientific and commercial drug development expertise, intellectual property support, and turnkey laboratory and office infrastructure to help build and scale globally competitive Canadian life sciences companies. It serves three primary constituencies: early-stage life sciences companies (its core customer), life sciences professionals across Canada (community), and mid-career executives (leadership development). The organization operates over 200,000 square feet of turnkey facilities across three locations: the Vancouver Innovation Centre (including the newly opened M4 Centre in April 2026), the Montreal Innovation Centre, and a Toronto office at the MaRS Centre. The business model is not traditional commercial revenue generation; adMare is funded through government grants, service and facility income, and reinvested returns from portfolio company exits. Its product and service platform spans three pillars: Company Building (pre-seed investment, scientific and commercial R&D, IP and business development support), Ecosystems (innovation centre facilities, the AbbVie Biotech Innovators Award, and the adMare Community digital platform hosted on Hivebrite with 2,000+ members), and Talent (the adMare Executive Institute, adMare Academy's BIS Program, and experiential learning). The adMare Institute operates as a policy research arm producing white papers on Canadian life sciences.
adMare has helped create 39 companies that have collectively attracted $2.5 billion in risk capital and achieved a combined value of $5.8 billion, while generating more than $130 million in cash returns that are reinvested into the Canadian ecosystem. Recent portfolio company activity includes the launch of 26therapeutics (March 2026, dry eye disease), seed funding of Ocythera (January 2026, rare bone disease), Series B participation in Kainova Thérapeutiques ($32M CAD, February 2026, immuno-oncology), and the naming of RIME Therapeutics as the April 2026 AbbVie Biotech Innovators Award recipient. The adMare Academy has trained 800+ alumni (91% employed in the life sciences industry) and the Executive Institute has developed nearly 150 executives from over 100 Canadian life sciences organizations. Federal government support has been a material funding source, with grants from Innovation, Science and Economic Development Canada ($5M, December 2023) and Pacific Economic Development Canada ($4.2M, February 2025). In March-April 2026, founding President and CEO Gordon McCauley transitioned to Vice-Chair, with nine-year adMare executive Matthew J. Carlyle appointed President, CEO, and Director; Frédéric Lemaître Auger was concurrently promoted to Executive Vice President, Investments.
adMare Bio Innovations firmographics
Firmographics- Name
- adMare Bio Innovations
- Legal name
- adMare BioInnovations
- Website
- https://admarebio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- adMare BioInnovations is a Canadian mission-driven life sciences platform that provides early-stage capital, scientific and commercial expertise, turnkey lab facilities, and talent development to build and scale Canadian biotech companies. To date, it has helped create 39 companies with $5.8 billion in combined value.
- Ownership category
- akta.pro rank
adMare Bio Innovations industry classification
Industry- Product category
- Life Sciences Company Creation & Biotech Venture Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)
Keywords
Where adMare Bio Innovations is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
adMare Bio Innovations business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Portfolio Returns and Reinvestment: adMare generates returns through its portfolio company exits (IPOs, M&A) and reinvests those returns back into the Canadian life sciences industry. The organization has generated more than $130 million in cash returns, which are plowed back into building new companies and supporting the ecosystem.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
adMare Bio Innovations product offering
Product offeringCore offering
adMare BioInnovations is a Canadian life sciences company creation engine that identifies breakthrough scientific discoveries and builds globally competitive biotech companies. It provides early-stage capital, scientific and commercial drug development expertise, turnkey laboratory and office infrastructure at Innovation Centres in Vancouver, Montreal, and Toronto, and industry-ready talent development programs, reinvesting returns from portfolio exits back into the Canadian life sciences ecosystem.
Product overview
adMare BioInnovations is Canada's life sciences company creation engine, offering a multi-component platform built around three pillars: (1) Company Building — providing early-stage capital, scientific expertise, commercial R&D, IP and business development support to create and scale globally competitive life sciences companies; (2) Ecosystems — operating turnkey lab and office facilities through Innovation Centres in Vancouver, Montreal, and Toronto (totaling more than 200,000 square feet), running the AbbVie Biotech Innovators Award competition, and maintaining the adMare Community digital networking platform; and (3) Talent — delivering the adMare Executive Institute (leadership development), BIS Program, and Experiential Learning programs. The adMare Institute provides policy research and white papers. adMare's portfolio includes 39 companies created to date, with a combined value of $5.8 billion.
Differentiator
Problem solved
Functional benefit
Brands
- adMare Executive Institute: Canada's premier leadership development program for experienced mid-career executives and emerging C-suite leaders in the life sciences sector.
- adMare Academy
- adMare Innovation Centre
- adMare Institute
- adMare Community
- AbbVie Biotech Innovators Award
Products and services
- adMare Innovation Centre – Vancouver Turnkey laboratory and office facilities at 2405 Wesbrook Mall, Vancouver, British Columbia, providing workspace for emerging life sciences companies.
- adMare Innovation Centre – Montreal Turnkey laboratory and office facilities at 7171 Frederick-Banting, Montréal, Québec, offering shared equipment and services for early-stage biotech companies.
- adMare Executive Institute Canada's premier leadership development program for experienced mid-career executives and emerging C-suite leaders in the life sciences sector, combining in-person workshops, virtual peer sessions, executive coaching, and real-world leadership challenges. Has trained nearly 150 participants from more than 100 organizations across Canada.
- AbbVie Biotech Innovators Award A national competition jointly run by AbbVie and adMare providing the winning Quebec biotech with one year of free laboratory and office space at the adMare Innovation Centre in Montreal, shared equipment access, and mentorship from AbbVie's scientific and business leaders.
- adMare Accelerator An accelerator program for early-stage life sciences ventures providing hands-on company building support, capital, and access to infrastructure.
- adMare Academy (BIS Program and Experiential Learning) Industry-ready talent development programs including the Business Innovation Studies (BIS) Program and experiential learning offerings that prepare individuals for careers in the Canadian life sciences industry. The Academy has trained more than 800 alumni, with 91% employed in the life sciences industry.
- adMare Community A digital ecosystem bringing together over 2,000 life sciences professionals from students to CEOs across Canada, hosted on the Hivebrite platform, enabling networking, collaboration, and knowledge sharing.
- Early-Stage Capital & Company Creation Pre-seed and early-stage investment capital provided to life sciences companies, with adMare co-investing alongside other investors to build globally competitive Canadian companies. To date, adMare has helped create 39 companies that have attracted $2.5 billion in risk capital.
- adMare Institute A policy research institute dedicated to advancing public policy issues in life sciences in Canada, producing white papers on capital flows, anchor companies, and ecosystem development.
- 26therapeutics Inc. Montreal-based life sciences company developing first-in-class topical small-molecule therapy for dry eye disease targeting meibomian gland dysfunction through CYP26B1 inhibition, created via adMare's company creation model.
Quantifiable outcome
- 39 companies created that have attracted $2.5 billion in risk capital and achieved $5.8 billion combined value
- +4 more outcomes
Companies that use adMare Bio Innovations
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles4 records
adMare Bio Innovations technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
adMare Bio Innovations partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core, minor and flagship.
- VoxCell BioInnovationcoreResearch partnership to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell's human-relevant vascularized cancer tissue models. Collaboration applies perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics.
- Life Sciences BCminorPartnership with Life Sciences BC for ecosystem development. Life Sciences BC executives attended the ribbon-cutting ceremony for new lab facilities at adMare's Vancouver innovation centre.
- AbbVieflagshipAbbVie and adMare jointly run the AbbVie Biotech Innovators Award program to support early-stage biotechnology companies in Quebec. The award provides lab/office space at the adMare Innovation Centre in Montreal, shared equipment access, and mentorship from AbbVie's scientific and business leaders. First awarded to RIME Therapeutics in April 2026.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
adMare Bio Innovations competitors and assessment
Company assessmentDirect peers
- Johnson & Johnson Innovation – JLABS: JLABS operates a global network of no-strings-attached biotech incubators offering turnkey lab space, equipment, and mentorship to early-stage companies. JLABS is the closest functional analog to adMare's Innovation Centre model, differing mainly in pharma sponsorship (J&J vs. AbbVie at adMare) and geographic spread (global vs. Canada-only).
- Bayer CoLaborator: Bayer's CoLaborator is a pharma-sponsored biotech incubator providing turnkey lab space and access to Bayer R&D expertise to early-stage companies, structurally similar to adMare's flagship AbbVie Biotech Innovators Award partnership and Innovation Centre residency model.
- MaRS Discovery District: Toronto-based innovation hub hosting life sciences and other tech startups with shared infrastructure, talent programs, and ecosystem services. MaRS shares adMare's Canadian mandate and integrated infrastructure-plus-talent model, though it is broader across sectors (health, cleantech, fintech) rather than focused exclusively on life sciences.
- Creative Destruction Lab (CDL): CDL is a Canadian seed-stage accelerator with a dedicated Health stream, offering mentorship from experienced operators and investors to science-based startups. CDL complements adMare's company-creation engine with a venture-build curriculum, sharing Canadian roots and a focus on scaling science-driven companies.
- BioEnterprise: BioEnterprise is a Canadian agri-food and life sciences commercialization accelerator offering advisory, capital access, and infrastructure to early-stage Canadian companies. It is comparable to adMare's role as a national commercialization platform, though narrower in life sciences sub-sectors.
- IndieBio: IndieBio is a biotech-specific accelerator providing seed funding, lab space, and mentorship to biology-based startups. Its biology-only mandate and intensive company-building support parallel adMare's Accelerator and Innovation Centre offerings for therapeutic-biologics and adjacent companies.
- Atlas Venture: Atlas Venture is a Boston-based early-stage biotech-focused VC firm that builds and funds new therapeutic companies from inception. It parallels adMare's pre-seed/seed creation model for therapeutic biotech, though it operates as a traditional VC rather than providing lab infrastructure.
Broad incumbents
- Flagship Pioneering: Flagship Pioneering is a large US biotech venture creation firm that conceives, launches, and operates biotech companies (e.g., Moderna). It is comparable to adMare as a company-creation platform for breakthrough life sciences, but operates at much greater scale and with a for-profit, venture-backed model rather than a Canadian non-profit structure.
- ARCH Venture Partners: ARCH is a US venture firm that partners with universities and research institutions to found biotech companies, similar to adMare's company-creation model drawing on Canadian academic science. ARCH operates at significantly larger fund scale and with a US/global mandate.
Regional players
- Velocity (Cambridge, UK): Velocity is a University of Cambridge-affiliated biotech incubator offering lab space, mentorship, and seed funding to UK life sciences startups. It is comparable to adMare's Innovation Centre+Accelerator model but serves a UK/European ecosystem rather than Canada.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
adMare Bio Innovations social profiles
Digital presenceadMare Bio Innovations financial estimates
Financial estimateRevenue estimate
Valuation estimate
adMare Bio Innovations leadership team
Management profileNumber of profiles
Profiles9 records
adMare Bio Innovations funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
adMare Bio Innovations M&A and investment
M&A and investmentM&A1 record
Investments14 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about adMare Bio Innovations
What does adMare Bio Innovations do?
adMare BioInnovations is a Canadian life sciences company creation engine that identifies breakthrough scientific discoveries and builds globally competitive biotech companies. It provides early-stage capital, scientific and commercial drug development expertise, turnkey laboratory and office infrastructure at Innovation Centres in Vancouver, Montreal, and Toronto, and industry-ready talent development programs, reinvesting returns from portfolio exits back into the Canadian life sciences ecosystem.
Is adMare Bio Innovations a public or private company?
adMare Bio Innovations is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was adMare Bio Innovations founded?
adMare Bio Innovations was founded in 2019. It employs 101 to 250 people.
Where is adMare Bio Innovations based?
adMare Bio Innovations is headquartered in Vancouver, Canada, in the North America region.
How does adMare Bio Innovations make money?
One revenue line is on record: portfolio Returns and Reinvestment.
Who are adMare Bio Innovations's main competitors?
Direct peers on record are Johnson & Johnson Innovation – JLABS, Bayer CoLaborator, MaRS Discovery District, Creative Destruction Lab (CDL), BioEnterprise, IndieBio and Atlas Venture. Broad incumbents are Flagship Pioneering and ARCH Venture Partners. Velocity (Cambridge, UK) is listed as a regional player.
Does adMare Bio Innovations have an API?
No public API is recorded for adMare Bio Innovations.
What industry is adMare Bio Innovations in?
adMare Bio Innovations's product category is Life Sciences Company Creation & Biotech Venture Development. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.